Internet server (*http://www.usitc.gov*). The public record for this investigation may be viewed on the Commission's electronic docket (EDIS) at *http://edis.usitc.gov*. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205–1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on October 16, 2012, based on a complaint filed on September 10, 2012, on behalf of South Alabama Medical Science Foundation of Mobile, Alabama (''SASF''); Merck & Cie of Altdorf, Switzerland (''Merck''); and Pamlab LLC of Covington, Louisiana (''Pamlab''). 77 FR 63336 (October 16, 2012). The complaint alleged violations of Section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, by reason of infringement of one or more of claims 37, 39, 40, 47, 66, 67, 73, 76, 78–81, 83, 84, 86–89, 91, 92, 94–97, 99, 100, 110, 111, 113, 117, and 121 of U.S. Patent No. 5,997,915; claims 22, 26, and 32–38 of U.S. Patent No. 6,673,381; claims 1, 4–6, and 15 of U.S. Patent No. 7,172,778; and claims 1–3, 5, 6, 8, 9, 11–15, and 19–22 of U.S. Patent No. 6,011,040. The Commission's notice of investigation named as respondents Gnosis SpA of Desio, Italy; Gnosis Bioresearch SA of Sant'Antonino, Switzerland; Gnosis USA Inc. of Doylestown, Pennsylvania; and Macoven Pharmaceuticals LLC of Magnolia, Texas.

On December 13, 2012, the Commission issued notice of its determination not to review an ID adding Viva Pharmaceuticals LLC as a new respondent. On February 4, 2013, the Commission issued notice of its determination not to review an ID to identify the new respondent as Viva Pharmaceuticals Inc. rather than Viva Pharmaceuticals LLC.

On May 10, 2013, complainants SASF, Merck, and Pamlab filed an unopposed corrected motion for leave to add Nestle Health Science-Pamlab Inc. (''NHS-Pamlab'') as a complainant and change Pamlab's name to Camline LLC. On June 11, 2013, the administrative law judge issued an ID (Order No. 12) granting the motion. The administrative law judge found good cause shown because NHS-Pamlab has acquired Pamlab and Pamlab was renamed following the acquisition. There were no petitions for review.

Having considered the ID and the relevant portions of the record, the Commission has determined not to review the subject ID. The complaint and notice of investigation are therefore amended to add a new complainant NHS-Pamlab and to rename Pamlab as Camline LLC.

This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and of section 210.42(h) of the Commission's Rules of Practice and Procedure (19 CFR 210.42(h)).

By order of the Commission.

Issued: July 8, 2013.

Lisa R. Barton,

Acting Secretary to the Commission.

[FR Doc. 2013–16707 Filed 7–11–13; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Notice of Lodging of Proposed Consent Decree under the Clean Air Act

On June 28, 2013, the Department of Justice lodged a proposed consent decree with the United States District Court for the Eastern District of Tennessee in the lawsuit entitled *United States and State of Tennessee* v. *King Pharmaceuticals LLC,* Civil Action No. 2:13-cv-00178.

The United States filed this lawsuit under the Clean Air Act. The complaint seeks injunctive relief and civil penalties for alleged violations at the defendant's pharmaceutical production facility in Bristol, Tennessee, of (1) Permits issued under the Tennessee State Implementation Plan, (2) federal emission standards for hazardous air pollutants for pharmaceutical production, and (3) Title V of the Clean Air Act. The consent decree requires the defendant to perform injunctive relief to correct the violations at the facility and to pay $2.2 million in civil penalties, of which half will go to the United States and the other half to the State of Tennessee.

The publication of this notice opens a period for public comment on the consent decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to *United States et al.* v. *King Pharmaceuticals LLC,* D.J. Ref. No. 90–5–2–1–10132. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail:

To submit comments:	*Send them to:*
By e-mail	*pubcomment-ees.enrd@usdoj.gov.*
By mail	Assistant Attorney General U.S. DOJ—ENRD P.O. Box 7611 Washington, D.C. 20044–7611.

During the public comment period, the consent decree may be examined and downloaded at this Justice Department Web site: *http://www.usdoj.gov/enrd/Consent_Decrees.html.* We will provide a paper copy of the consent decree upon written request and payment of reproduction costs. Please mail your request and payment to: Consent Decree Library, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611.

Please enclose a check or money order for $13.00 (25 cents per page reproduction cost) payable to the United States Treasury.

Maureen Katz,

Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 2013–16752 Filed 7–11–13; 8:45 am]

BILLING CODE 4410–15–P

DEPARTMENT OF LABOR

Office of the Secretary

Agency Information Collection Activities; Submission for OMB Review; Comment Request; Labor Organization and Auxiliary Reports

ACTION: Notice.

SUMMARY: The Department of Labor (DOL) is submitting the Office of Labor Management Standards (OLMS) sponsored information collection request (ICR) revision titled, ''Labor Organization and Auxiliary Reports,'' to the Office of Management and Budget (OMB) for review and approval for use in accordance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C. 3501 *et seq.*).

DATES: Submit comments on or before August 12, 2013.

ADDRESSES: A copy of this ICR with applicable supporting documentation; including a description of the likely respondents, proposed frequency of response, and estimated total burden may be obtained free of charge from the RegInfo.gov Web site at *http://www.reginfo.gov/public/do/PRAViewICR?ref_nbr=201306-1245-001* (this link will only become active on the day following publication of this notice) or by contacting Michel Smyth by telephone